X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $104.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 18, 2021
Details:
Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (“VEGFR”) 1/2/3. Fruquintinib was approved by the China National Medical Products Administration (“NMPA”) in September 2018 under the brand name Elunate®.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Fruquintinib
Therapeutic Area: Oncology Product Name: Elunate
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Baring Private Equity Asia
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Agreement April 08, 2021
Details:
The agreement will aid in company's business growth as it looks to ramp up its oncology revenues from ELUNATE®, SULANDA® and the potential upcoming approval of savolitinib, likely to be a first-in-class selective c-MET inhibitor in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Surufatinib
Therapeutic Area: Oncology Product Name: Sulanda
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
The NMPA approval of Sulanda® was based on results from the SANET-ep study. The Phase III SANET-ep trial demonstrated surufatinib reduced risk of progressio
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
